NCT03891524 (AXIOMATIC-TKR) is a Phase 2 clinical trial of JNJ-70033093 25 mg in Arthroplasty, Replacement, Knee, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT03891524?

NCT03891524 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT03891524?

Interventions in NCT03891524: JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg.

What condition does NCT03891524 study?

NCT03891524 studies Arthroplasty, Replacement, Knee.

Is NCT03891524 still recruiting?

NCT03891524 is currently completed. Last updated 30 March 2025.

Are results published for NCT03891524?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-03-30 · How we verify

NCT03891524: AXIOMATIC-TKR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

Completed Phase 2 Results posted Last updated 30 March 2025

What this trial tests

Phase 2 trial testing JNJ-70033093 25 mg in Arthroplasty, Replacement, Knee in 1,242 participants. Completed in 6 April 2021.

Timeline

17 June 2019

Primary endpoint
6 April 2021

6 April 2021

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	1,242
Start date	17 June 2019
Primary completion	6 April 2021
Estimated completion	6 April 2021
Sites	117 locations across Italy, South Africa, Japan, Russia, Greece, Ukraine, Belgium, Israel

Drugs / interventions tested

JNJ-70033093 25 mg — full drug profile →
JNJ-70033093 50 mg — full drug profile →
JNJ-70033093 100 mg — full drug profile →
JNJ-70033093 200 mg — full drug profile →
Placebo
Enoxaparin 40 mg — full drug profile →

Conditions studied

Arthroplasty, Replacement, Knee — all drugs for Arthroplasty, Replacement, Knee →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

50 and older, any sex, with Arthroplasty, Replacement, Knee. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated) Primary · Up to Day 14

Total VTE was defined as the composite of clinical events committee (CEC)-adjudicated proximal and/or distal Deep Vein Thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death.

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	7
JNJ-70033093 50 mg Once Daily + Placebo	30
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	27
JNJ-70033093 50 mg BID	14
JNJ-70033093 200 mg Once Daily + Placebo	8
JNJ-70033093 100 mg + Placebo BID	12
JNJ-70033093 200 mg BID	10
Enoxaparin 40 mg Once Daily	54

Number of Participants With Any Bleeding Event (CEC-adjudicated) Secondary · Up to Day 14; Up to Day 52

Any bleeding was defined as the composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria modified for the surgical setting, clinically relevant nonmajor bleeding events, or minimal bleeding events as assessed by the CEC.

Up to Day 14

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	8
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	2
JNJ-70033093 50 mg BID	7
JNJ-70033093 200 mg Once Daily + Placebo	11
JNJ-70033093 100 mg + Placebo BID	7
JNJ-70033093 200 mg BID	6
Enoxaparin 40 mg Once Daily	12

Up to Day 52

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	8
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	2
JNJ-70033093 50 mg BID	7
JNJ-70033093 200 mg Once Daily + Placebo	11
JNJ-70033093 100 mg + Placebo BID	7
JNJ-70033093 200 mg BID	6
Enoxaparin 40 mg Once Daily	12

Number of Participants With Total VTE (CEC-adjudicated) Secondary · Up to Day 52

Total VTE was defined as the composite of (CEC-adjudicated) proximal and/or DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death.

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	7
JNJ-70033093 50 mg Once Daily + Placebo	30
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	27
JNJ-70033093 50 mg BID	14
JNJ-70033093 200 mg Once Daily + Placebo	8
JNJ-70033093 100 mg + Placebo BID	12
JNJ-70033093 200 mg BID	10
Enoxaparin 40 mg Once Daily	54

Number of Participants With Composite of Major and Clinically Relevant Nonmajor Bleeding (CRNM) Events (CEC-adjudicated) Secondary · Up to Day 14, Up to Day 52

Composite of Major bleeding event (BE): Fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; surgical site bleeding that requires second intervention open, arthroscopic, endovascular,or hemarthrosis resulting in prolonged hospitalization, deep wound infection and/or either unexpected and prolonged and/or sufficiently large

Up to Day 14

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	2
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	2
JNJ-70033093 200 mg Once Daily + Placebo	1
JNJ-70033093 100 mg + Placebo BID	1
JNJ-70033093 200 mg BID	1
Enoxaparin 40 mg Once Daily	5

Up to Day 52

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	2
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	2
JNJ-70033093 200 mg Once Daily + Placebo	2
JNJ-70033093 100 mg + Placebo BID	1
JNJ-70033093 200 mg BID	1
Enoxaparin 40 mg Once Daily	5

Number of Participants With Major Bleeding Events (CEC-adjudicated) Secondary · Up to Day 14; Up to Day 52

Number of participants with major BE (adjudicated by CEC) were reported. Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or

Up to Day 14

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	0
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	0
JNJ-70033093 200 mg Once Daily + Placebo	0
JNJ-70033093 100 mg + Placebo BID	0
JNJ-70033093 200 mg BID	0
Enoxaparin 40 mg Once Daily	1

Up to Day 52

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	0
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	0
JNJ-70033093 200 mg Once Daily + Placebo	0
JNJ-70033093 100 mg + Placebo BID	0
JNJ-70033093 200 mg BID	0
Enoxaparin 40 mg Once Daily	1

Number of Participants With CRNM Bleeding Events (CEC-adjudicated) Secondary · Up to Day 14; Up to Day 52

Number of participants with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.

Up to Day 14

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	2
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	2
JNJ-70033093 200 mg Once Daily + Placebo	1
JNJ-70033093 100 mg + Placebo BID	1
JNJ-70033093 200 mg BID	1
Enoxaparin 40 mg Once Daily	4

Up to Day 52

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	2
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	2
JNJ-70033093 200 mg Once Daily + Placebo	2
JNJ-70033093 100 mg + Placebo BID	1
JNJ-70033093 200 mg BID	1
Enoxaparin 40 mg Once Daily	4

Number of Participants With Minimal Bleeding Events (CEC-adjudicated) Secondary · Up to Day 14; Up to Day 52

Number of participants with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma.

Up to Day 14

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	6
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	2
JNJ-70033093 50 mg BID	5
JNJ-70033093 200 mg Once Daily + Placebo	8
JNJ-70033093 100 mg + Placebo BID	7
JNJ-70033093 200 mg BID	4
Enoxaparin 40 mg Once Daily	8

Up to Day 52

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	6
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	2
JNJ-70033093 50 mg BID	5
JNJ-70033093 200 mg Once Daily + Placebo	9
JNJ-70033093 100 mg + Placebo BID	7
JNJ-70033093 200 mg BID	5
Enoxaparin 40 mg Once Daily	8

Number of Participants With Major or CRNM Bleeding Events (CEC-adjudicated) Secondary · Up to Day 14; Up to Day 52

Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acut

Up to Day 14

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	2
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	2
JNJ-70033093 200 mg Once Daily + Placebo	1
JNJ-70033093 100 mg + Placebo BID	1
JNJ-70033093 200 mg BID	1
Enoxaparin 40 mg Once Daily	5

Up to Day 52

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	2
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	2
JNJ-70033093 200 mg Once Daily + Placebo	2
JNJ-70033093 100 mg + Placebo BID	1
JNJ-70033093 200 mg BID	1
Enoxaparin 40 mg Once Daily	5

Number of Participants With Major VTE (CEC-adjudicated) Secondary · Up to Day 52

Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death.

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	2
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	1
JNJ-70033093 50 mg BID	1
JNJ-70033093 200 mg Once Daily + Placebo	0
JNJ-70033093 100 mg + Placebo BID	2
JNJ-70033093 200 mg BID	0
Enoxaparin 40 mg Once Daily	4

Number of Participants With Major VTE (CEC-adjudicated) Secondary · Up to Day 14

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	2
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	1
JNJ-70033093 50 mg BID	1
JNJ-70033093 200 mg Once Daily + Placebo	0
JNJ-70033093 100 mg + Placebo BID	2
JNJ-70033093 200 mg BID	0
Enoxaparin 40 mg Once Daily	4

Number of Participants With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated) Secondary · Up to Day 14

Number of participants with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

Asymptomatic

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	0
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	0
JNJ-70033093 200 mg Once Daily + Placebo	0
JNJ-70033093 100 mg + Placebo BID	0
JNJ-70033093 200 mg BID	0
Enoxaparin 40 mg Once Daily	1

Symptomatic

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	0
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	0
JNJ-70033093 200 mg Once Daily + Placebo	0
JNJ-70033093 100 mg + Placebo BID	0
JNJ-70033093 200 mg BID	0
Enoxaparin 40 mg Once Daily	0

Number of Participants With Proximal DVT (CEC-adjudicated) Secondary · Up to Day 52

Number of participants with proximal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.

Asymptomatic

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	0
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	0
JNJ-70033093 200 mg Once Daily + Placebo	0
JNJ-70033093 100 mg + Placebo BID	0
JNJ-70033093 200 mg BID	0
Enoxaparin 40 mg Once Daily	1

Symptomatic

Group	Value	95% CI
JNJ-70033093 25 mg Once Daily + Placebo	0
JNJ-70033093 50 mg Once Daily + Placebo	0
JNJ-70033093 25 mg + Placebo Twice Daily (BID)	0
JNJ-70033093 50 mg BID	0
JNJ-70033093 200 mg Once Daily + Placebo	0
JNJ-70033093 100 mg + Placebo BID	0
JNJ-70033093 200 mg BID	0
Enoxaparin 40 mg Once Daily	0

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 6 weeks. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

JNJ-70033093 25 mg Once Daily + Placebo

Serious: 1/33 (3%)

Deaths: 0/33

JNJ-70033093 50 mg Once Daily + Placebo

Serious: 2/150 (1%)

Deaths: 0/150

JNJ-70033093 25 mg + Placebo Twice Daily (BID)

Serious: 5/148 (3%)

Deaths: 0/148

JNJ-70033093 50 mg BID

Serious: 5/148 (3%)

Deaths: 0/148

JNJ-70033093 200 mg Once Daily + Placebo

Serious: 2/147 (1%)

Deaths: 0/147

JNJ-70033093 100 mg + Placebo BID

Serious: 5/149 (3%)

Deaths: 0/149

JNJ-70033093 200 mg BID

Serious: 2/148 (1%)

Deaths: 0/148

Enoxaparin 40 mg Once Daily

Serious: 11/296 (4%)

Deaths: 1/296

Serious adverse events (29 terms)

Reaction	System	JNJ-70033093 25 mg Once Da…	JNJ-70033093 50 mg Once Da…	JNJ-70033093 25 mg + Place…	JNJ-70033093 50 mg BID	JNJ-70033093 200 mg Once D…	JNJ-70033093 100 mg + Plac…	JNJ-70033093 200 mg BID	Enoxaparin 40 mg Once Daily
Deep Vein Thrombosis	Vascular disorders	—	—	—	—	—	—	—	—
Atrial Fibrillation	Cardiac disorders	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Non-Cardiac Chest Pain	General disorders	—	—	—	—	—	—	—	—
Covid-19	Infections and infestations	—	—	—	—	—	—	—	—
Device Related Infection	Infections and infestations	—	—	—	—	—	—	—	—
Urosepsis	Infections and infestations	—	—	—	—	—	—	—	—
Wound Infection	Infections and infestations	—	—	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Craniocerebral Injury	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Periprosthetic Fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Subdural Haemorrhage	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Cardiovascular Evaluation	Investigations	—	—	—	—	—	—	—	—
Full Blood Count Decreased	Investigations	—	—	—	—	—	—	—	—
Haemoglobin Decreased	Investigations	—	—	—	—	—	—	—	—
Electrolyte Imbalance	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Compartment Syndrome	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Rhabdomyolysis	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Ischaemic Stroke	Nervous system disorders	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Pulmonary Embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—

Other adverse events (1 terms — click to expand)

Reaction	System	JNJ-70033093 25 mg Once Da…	JNJ-70033093 50 mg Once Da…	JNJ-70033093 25 mg + Place…	JNJ-70033093 50 mg BID	JNJ-70033093 200 mg Once D…	JNJ-70033093 100 mg + Plac…	JNJ-70033093 200 mg BID	Enoxaparin 40 mg Once Daily
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—

Most-reported serious reactions: Deep Vein Thrombosis, Atrial Fibrillation, Diarrhoea, Vomiting, Non-Cardiac Chest Pain, Covid-19, Device Related Infection, Urosepsis.

Data from ClinicalTrials.gov NCT03891524 adverse events section.

Sponsor's own description

The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis \[DVT\] \[asymptomatic confirmed by venography assessment or objectively confirmed symptomatic\], nonfatal pulmonary embolism \[PE\], or any death) during the treatment period.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Milvexian for the Prevention of Venous Thromboembolism.
Weitz JI, Strony J, Ageno W, Gailani D, et al · · 2021 · cited 193× · PMID 34780683 · DOI 10.1056/nejmoa2113194
Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence.
Nopp S, Kraemmer D, Ay C. · · 2022 · cited 61× · PMID 35647061 · DOI 10.3389/fcvm.2022.903029
Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).
Al-Horani RA. · · 2020 · cited 40× · PMID 31847619 · DOI 10.1080/13543776.2020.1705783
The rebirth of the contact pathway: a new therapeutic target.
Srivastava P, Gailani D. · · 2020 · cited 34× · PMID 32740037 · DOI 10.1097/moh.0000000000000603
Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives.
Poenou G, Dumitru Dumitru T, Lafaie L, Mismetti V, et al · · 2022 · cited 26× · PMID 35707632 · DOI 10.2147/vhrm.s331614
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022.
Tamargo J, Agewall S, Borghi C, Ceconi C, et al · · 2023 · cited 25× · PMID 37169875 · DOI 10.1093/ehjcvp/pvad034
Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy.
Presume J, Ferreira J, Ribeiras R. · · 2024 · cited 13× · PMID 38306010 · DOI 10.1007/s40119-024-00352-x
Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances.
Xia Y, Hu Y, Tang L. · · 2023 · cited 12× · PMID 37375813 · DOI 10.3390/ph16060866

Verify or expand the search:

Other recruiting trials for Arthroplasty, Replacement, Knee

Currently open trials in the same condition.

NCT07337772 — Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty · NA · recruiting
NCT07058623 — Nurse-Led Telehealth vs In-Person Follow-Up After Total Knee Replacement · NA · recruiting
NCT05992064 — Wearable Sensors for Monitoring Recovery After Total Knee Arthroplasty · recruiting
NCT05518513 — Continuous Infusion and Intermittent Bolus Adductor Canal Block for Total Knee Arthroplasty · NA · recruiting
NCT04884542 — Multigen Plus H Study and AMF TT Cones · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03891524 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 30 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03891524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03891524: AXIOMATIC-TKR

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (29 terms)

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Arthroplasty, Replacement, Knee

Other Janssen Research & Development, LLC trials

Verify against primary sources